Zymeworks Signs Definitive Agreement to Acquire Theravance Biopharma
Zymeworks Inc. has signed a definitive agreement to acquire Theravance Biopharma, Inc., marking a strategic step in expanding its commercial portfolio. The acquisition will bring YUPELRI®, the first and only once-daily nebulized long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), into Zymeworks' partnered asset portfolio, reinforcing the company's commitment to addressing serious diseases and improving patient outcomes.
Following the completion of the transaction, YUPELRI® is expected to generate near-term commercial r...
